Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Core Insights - Inhibrx Biosciences (NASDAQ: INBX) is a spinoff from the original Inhibrx, which was funded through a merger with a Sanofi subsidiary in May 2024 [1] Company Overview - Inhibrx has two pipeline candidates that are currently under development [1] - The company is focused on educating investors about the science behind its business and the importance of due diligence in biotech investments [1]